Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Industrie
• Propriété intellectuelle
• Santé

Détails sur l'objet

Politique ou Programme

• Research and Development General awareness on the importance of a strong research and development ecosystem in Canada to support ultra rare disease patients
• Science and Technology The importance of including science and technology, and Canada's innovation potential, in federal policies

Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement

• Industry Patent Act, R.S.C., 1985, c. P-4. The Act as a whole falls under the jurisdiction of the Minister of Industry, with the exception of sections 79 to 103 pertaining to the Patented Medicines Pricing Review Board (PMPRB), which are the responsibility of the Minister of Health. The Minister of Health has launched a public consultation process which may amend the act, change regulations, and/or result in new policies or programs. Alexion Pharma Canada is participating in these consultations, and will raise awareness on how proposed changes will impact the life sciences industry in Canada and specifically development of innovative new treatments for rare diseases

Règlement

• Health - Patent Act, R.S.C., 1985, c. P-4. The Act as a whole falls under the jurisdiction of the Minister of Industry, with the exception of sections 79 to 103 pertaining to the Patented Medicines Pricing Review Board (PMPRB), which are the responsibility of the Minister of Health. The Minister of Health has launched a public consultation process which may amend the act, change regulations, and/or result in new policies or programs. Alexion Pharma Canada is participating in these consultations
• Intellectual Property Amendments to the Food and Drugs Act: Guide to New Authorities (power to disclose information). Alexion wishes to raise awareness of the importance of considering intellectual property protection when deciding whether to make Confidential Business Information available to third-parties as Health Canada considers guidelines for the bill formerly referred to as C-17.

Techniques de communication

• Communication écrite
• Communication orale

Institutions gouvernementales

• Affaires mondiales Canada (AMC)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Santé Canada (SC)

Adresse :
3100 Rutherford Road
Vaughan, ON  L4K 0G6
Canada

Numéro de téléphone : 416-356-3022

Renseignements sur la société mère